Deutsche Bank Reports on Auxilium Pharmaceuticals (AUXL)

In a report released today, Deutsche Bank commented on Auxilium Pharmaceuticals AUXL. In the report, Deutsche Bank was bullish on the company. Deutsche Bank writes, “Our Buy investment rating on Auxilium is predicated on the significant commercial opportunity for Xiaflex, coupled with a still solid growth outlook for Testim. We believe that Xiaflex, the company's potential flagship, non-surgical treatment for Dupuytren's contracture, could have peak sales potential of $400M+ in the US. Following the Q1 results, Auxilium shares continue to look attractive.” Deutsche Bank has a Buy rating on the company and a price target of $28.00. Shares of the pharmaceutical closed at $22.55, down from the opening price of $22.27.